ESR1 and inflammatory breast carcinoma: A recent study illuminated that almost 20% of the patients with ER+/PR− and HER2-negative were non-luminal-like and didn’t benefit from sufficient endocrine therapy12, which partly explains the worse outcome for IBC with ER+/PR− phenotype.